Get the Stockscreener App
25.48
2.17%
0.54
After Hours:
25.48
Zymeworks Inc. stock is traded at $25.48, with a volume of 656.36K.
It is up +2.17% in the last 24 hours and up +31.54% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$24.94
Open:
$26.28
24h Volume:
656.36K
Relative Volume:
0.60
Market Cap:
$1.92B
Revenue:
$122.87M
Net Income/Loss:
$-73.68M
P/E Ratio:
-25.99
EPS:
-0.9803
Net Cash Flow:
$-39.27M
1W Performance:
-4.53%
1M Performance:
+31.54%
6M Performance:
+94.50%
1Y Performance:
+101.90%
1-Day Range:
$25.44
$26.46
1-Week Range:
$24.79
$27.49
52-Week Range:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
25.48 | 1.88B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Zymeworks (NYSE:ZYME) Shares Gap UpWhat's Next? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's What Happened - MarketBeat
EcoR1 Capital LLC Increases Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Zymeworks (ZYME) Receives Rating Upgrade and Increased Price Tar - GuruFocus
Redmile Group LLC Sells 638,318 Shares of Zymeworks Inc. $ZYME - MarketBeat
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Delta Optimist
Norges Bank Buys New Shares in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks to Engage in Key Investor Conferences - MSN
Zymeworks (ZYME) Is Up 5.2% After First FDA Approval For Zanidatamab And Royalty ShiftHas The Bull Case Changed? - Sahm
Zymeworks (ZYME): Reassessing Valuation After FDA Zanidatamab Approval and a Sharp Share Price Rally - Sahm
Zymeworks Inc Stock Analysis and ForecastPrice Momentum Alerts & Low Entry Investment Plans - earlytimes.in
How higher bond yields impact Zymeworks Inc. (ZA8) stockPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsPortfolio Value Report & Long Hold Capital Preservation Tips - Newser
What technical patterns form on Zymeworks Inc. (ZA8) stock chartsWeekly Gains Summary & Short-Term Swing Trade Alerts - Newser
Is Zymeworks Inc. (ZA8) stock considered safe havenInsider Selling & AI Powered Market Trend Analysis - Newser
Will Zymeworks Inc. (ZA8) stock maintain strong growth2025 Earnings Impact & Safe Capital Allocation Plans - Newser
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
Citizens Initiates Coverage of Zymeworks (ZYME) with Market Outperform Recommendation - Nasdaq
How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Gainers & Verified Technical Signals - Newser
Zymeworks Announces Participation in Upcoming Conferences - The Manila Times
Zymeworks Inc. Announces Participation in ASCO GI and J.P. Morgan Healthcare Conference, Highlighting Advances in HER2-Driven Gastrointestinal Cancers and Novel Drug Developments - Quiver Quantitative
Is Zymeworks Inc. (ZA8) stock supported by strong fundamentalsAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN
Is Zymeworks Inc a good long term investmentMarket Capitalization Trends & Join a Community of Smart Investors - earlytimes.in
Zymeworks Inc. $ZYME Stock Position Lifted by Tejara Capital Ltd - MarketBeat
Zymeworks (ZYME) Is Up 13.8% After Positive Zanidatamab Trial and Share Buyback PlanWhat's Changed - simplywall.st
Zymeworks (NASDAQ:ZYME) Stock Price Up 8%Time to Buy? - MarketBeat
Zymeworks (NYSE:ZYME) Trading Up 6.1%Here's Why - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Zymeworks (NYSE:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
A Look at Zymeworks (ZYME) Valuation Following $125M Buyback and Positive Zanidatamab Phase 3 Results - Sahm
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN
Zymeworks stock hits 52-week high at 26.2 USD By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Sees Large Volume IncreaseHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 26.2 USD - Investing.com
Zymeworks Inc.Common Stock (Nasdaq:ZYME) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Zymeworks Announces Participation in Upcoming Investor Conferences - lelezard.com
Shareholder Miller Files To Sell 118,000 Of Zymeworks Inc [ZYME] - TradingView
Hillsdale Investment Management Inc. Lowers Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. Management to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
Zymeworks (NASDAQ: ZYME) to Join Evercore, Citi 2025 Healthcare Conferences - Stock Titan
Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan - The Globe and Mail
Zymeworks Inc. (NASDAQ:ZYME) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):